CN118234727A - 用于疗法的6H-咪唑并[1,2-a]吡咯并[2,3-e]吡啶衍生物 - Google Patents

用于疗法的6H-咪唑并[1,2-a]吡咯并[2,3-e]吡啶衍生物 Download PDF

Info

Publication number
CN118234727A
CN118234727A CN202280059586.1A CN202280059586A CN118234727A CN 118234727 A CN118234727 A CN 118234727A CN 202280059586 A CN202280059586 A CN 202280059586A CN 118234727 A CN118234727 A CN 118234727A
Authority
CN
China
Prior art keywords
formula
compound
cancer
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280059586.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·穆林
J-F·佩罗奈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN118234727A publication Critical patent/CN118234727A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280059586.1A 2021-07-16 2022-07-12 用于疗法的6H-咪唑并[1,2-a]吡咯并[2,3-e]吡啶衍生物 Pending CN118234727A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306000 2021-07-16
EP21306000.7 2021-07-16
PCT/EP2022/069471 WO2023285465A1 (en) 2021-07-16 2022-07-12 6h-imidazo[1,2-a]pyrrolo[2,3-e]pyridine derivatives for use in therapy

Publications (1)

Publication Number Publication Date
CN118234727A true CN118234727A (zh) 2024-06-21

Family

ID=77126713

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280059586.1A Pending CN118234727A (zh) 2021-07-16 2022-07-12 用于疗法的6H-咪唑并[1,2-a]吡咯并[2,3-e]吡啶衍生物

Country Status (7)

Country Link
US (1) US20240294529A1 (https=)
EP (1) EP4370516A1 (https=)
JP (1) JP2024525792A (https=)
CN (1) CN118234727A (https=)
AR (1) AR126473A1 (https=)
TW (1) TW202320753A (https=)
WO (1) WO2023285465A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024525791A (ja) * 2021-07-16 2024-07-12 サノフイ 治療に使用するためのイミダゾ［１，２－ｂ］［１，２，４］トリアゾール誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2928922B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2928924B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
FR2950344B1 (fr) * 2009-09-18 2011-11-25 Sanofi Aventis Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.
CA3084139C (en) * 2017-11-15 2023-02-28 Korea Research Institute Of Bioscience And Biotechnology Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound

Also Published As

Publication number Publication date
US20240294529A1 (en) 2024-09-05
JP2024525792A (ja) 2024-07-12
TW202320753A (zh) 2023-06-01
EP4370516A1 (en) 2024-05-22
AR126473A1 (es) 2023-10-11
WO2023285465A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
US11827644B2 (en) Pyrazine derivative and application thereof in inhibiting SHP2
WO2021121371A1 (zh) Kras g12c抑制剂及其在医药上的应用
EP4006026A1 (en) Class of triaromatic compounds targeting bifunctional phosphorylation site of stat3 and applications thereof
CN116354960A (zh) Shp2磷酸酶抑制剂
CN117088878A (zh) 一种高活性Wnt通路抑制剂化合物
CN114456178B (zh) 四氢嘧啶[1,2-b]吲唑-4-胺类衍生物作为AhR抑制剂的用途及制备方法
CN112321568B (zh) 4-甲基吡咯取代的吲哚酮衍生物、其制备方法及其医药用途
CN118234727A (zh) 用于疗法的6H-咪唑并[1,2-a]吡咯并[2,3-e]吡啶衍生物
CN115246863B (zh) 一种川芎嗪四价铂类化合物、其制备方法及其用途
CN117916240A (zh) 用于疗法的咪唑并[1,2-b][1,2,4]三唑衍生物
CN110698471A (zh) Ask1抑制剂及其应用
CN110407839A (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
CN110467616A (zh) 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN113135938B (zh) 取代的大环类酪氨酸激酶抑制剂及其用途
US10301325B2 (en) Quinoline derivative, and pharmaceutical composition, preparation method and use thereof
JPWO2017135259A1 (ja) 共結晶
JP7354245B2 (ja) ピロロピリミジン骨格を有する新規なカーボネート化合物又はその薬学的に許容可能な塩
WO2001005402A1 (en) Preventive and therapeutic agents for cancer
CN111991398B (zh) 苯并哒嗪类化合物在制备sost蛋白抑制剂中的应用
WO2022161263A1 (zh) 新型Hedgehog信号通路抑制剂
KR101796075B1 (ko) 트리아졸로 퀴나졸린디온 유도체
WO2024174949A1 (zh) 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
CN107266468A (zh) 含吡唑啉结构的噻喃并嘧啶类化合物的制备及应用
CN118561945A (zh) 18β-甘草次酸酯类衍生物及其制备方法和用途
WO2002100835A1 (en) Heterocyclic compounds having antitumor activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination